GENOCEA BIOSCIENCES, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation
Change in fair value of warrant liability
Gain on sale of equipment
Write-off of deferred financing fees
Asset impairment
Allocation of proceeds to transaction expenses
Non-cash interest expense
Amortization of Debt Issuance Costs and Discounts
Other
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Right-of-use assets, net of lease liabilities
Other non-current assets
Accounts payable
Deferred revenue
Accrued expenses and other liabilities

Net cash used in operating activities
Deferred Revenue, Period Increase (Decrease)
Net cash used in operating activities

Investing activities
Purchases of property and equipment
Proceeds from sale of equipment
Proceeds from maturities of investments
Purchases of investments
Net cash (used in) provided by investing activities
Net cash used in investing activities

Financing activities
Proceeds from long-term debt
Proceeds from issuance of common stock, net
Underwritten public offering
Total proceeds from issuance of common stock, net

Proceeds from underwritten public offering, net of issuance costs
Payment of deferred financing costs
Proceeds from issuance of long-term debt, net of issuance costs
Proceeds from issuance of common stock under employee benefit plans
Net cash provided by (used in) financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Payments on finance lease
Repayment of long-term debt
Proceeds from exercise of stock options
Payments of Financing Costs
Payment for Debt Extinguishment or Debt Prepayment Cost
Net cash provided by financing activities
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Non-cash financing activities and supplemental cash flow information
Right-of-use asset obtained in exchange for lease liabilities
Cash paid in connection with operating lease liabilities
Capital Expenditures Incurred but Not yet Paid
Cash paid for interest
Warrants issued in connection with debt modification

Comments